<DOC>
	<DOCNO>NCT00579254</DOCNO>
	<brief_summary>To assess effect single pill therapy management hypertension cardiovascular risk factor ( e.g. , dyslipidemia ) Indian patient treat doctor already consider administration amlodipine/atorvastatin single pill appropriate</brief_summary>
	<brief_title>Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors</brief_title>
	<detailed_description>Patients prescribe single pill Caduet eligible participate study . The treat physician obtain write informed consent subject subject 's legally acceptable representative study-specific activity perform . The study terminate May 5 , 2008 . The decision terminate due inability achieve study timeline undue delay obtain IEC/IRB permission site . No safety efficacy issue cause decision terminate .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Amlodipine , atorvastatin drug combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients prescribe single pill Caduet eligible participate study . Patients treat study accord prevail local clinical practice follow locally approve product label recommendation . Known hypersensitivity dihydropyridines , amlodipine , atorvastatin , component medication , Active liver disease unexplained persistent elevation serum transaminase exceed three time upper limit normal , Or pregnant , breastfeeding , childbearing potential use adequate contraceptive measure . Amlodipine/atorvastatin administer woman childbearing age patient highly unlikely conceive inform potential hazard fetus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Efficacy , safety &amp; tolerability Caduet In Patients With Cardiovascular Risk Factors</keyword>
</DOC>